4 Einträge gefunden

1. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer

   1. Nitz, Ulrike A
   2. Gluz, Oleg
   3. Kümmel, Sherko
   4. Christgen, Matthias
   5. Braun, Michael
   6. Aktas, Bahriye
   7. Lüdtke-Heckenkamp, Kerstin

   2022 - Forschungsinformationssystem des UKE
3. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

   1. Graeser, Monika
   2. Harbeck, Nadia
   3. Gluz, Oleg
   4. Würstlein, Rachel
   5. Zu Eulenburg, Christine
   6. Schumacher, Claudia
   7. Grischke, Eva-Maria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials: Combined analysis from the WSG ADAPT subtrials

   1. Graeser, Monika
   2. Schrading, Simone
   3. Gluz, Oleg
   4. Strobel, Kevin
   5. Würstlein, Rachel
   6. Kümmel, Sherko
   7. Schumacher, Claudia

   2021 - Forschungsinformationssystem des UKE - frei zugänglich